약물 관련 악골 괴사증 (MRONJ) 환자에서 Pentoxifylline and Tocopherol의 효과: 문헌고찰
Effect of pentoxifylline and tocopherol for MRONJ patients: A systematic review
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
MRONJ (medication related osteonecrosis of the jaw) is a disease characterized by necrosis of the jaw that occurs after administration of anti-resorptive or anti-angiogenic drugs. However, etiology and effective treatment methods of MRONJ are not yet clearly identified. In this study, a systematic review was conducted to investigate the effects of pentoxifylline and tocopherol on MRONJ. A total of 5 clinical studies using pentoxifyllie and tocopherol in MRONJ patients among the papers registered in Pubmed/medline were reviewed. Pentoxifyllie and tocopherol were used for therapeutic purposes in 32 patients, and the mean age was 68 years for men and 74.21 years for women. Of the 32 patients, 20 patients were stage 2, 11 patients were stage 3, and one patient was stage 0. In the most cases, the triggering factor was extraction. All patients complained of pain in the lesion area before drugs administration. The average follow-up period was 10.6 months. After drugs administration, 29 patients (90.6%) showed improvement in symptoms in terms of bone exposure and pain. Administration of pentoxifylline and tocopherol in MRONJ may improve symptoms of pain and bone exposure. However, it seems that additional studies on the appropriate use and dose, timing and duration of administration are needed.
Abstract
MRONJ (medication related osteonecrosis of the jaw) is a disease characterized by necrosis of the jaw that occurs after administration of anti-resorptive or anti-angiogenic drugs. However, etiology and effective treatment methods of MRONJ are not yet clearly identified. In this study, a systematic review was conducted to investigate the effects of pentoxifylline and tocopherol on MRONJ. A total of 5 clinical studies using pentoxifyllie and tocopherol in MRONJ patients among the papers registered in Pubmed/medline were reviewed. Pentoxifyllie and tocopherol were used for therapeutic purposes in 32 patients, and the mean age was 68 years for men and 74.21 years for women. Of the 32 patients, 20 patients were stage 2, 11 patients were stage 3, and one patient was stage 0. In the most cases, the triggering factor was extraction. All patients complained of pain in the lesion area before drugs administration. The average follow-up period was 10.6 months. After drugs administration, 29 patients (90.6%) showed improvement in symptoms in terms of bone exposure and pain. Administration of pentoxifylline and tocopherol in MRONJ may improve symptoms of pain and bone exposure. However, it seems that additional studies on the appropriate use and dose, timing and duration of administration are needed.
참고문헌 (31)
- Robert E Marx, "Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic", Journal of Oral and Maxillofacial Surgery, 61(9), pp.1115~1117 (2003), Elsevier BV[DOI]
- Sivolella S, "Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease", Anticancer Res, 33(5), pp.1793~1797 (2013)
- Daria Pakosch, "Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab", Oral and Maxillofacial Surgery, 17(4), pp.303~306 (2012), Springer Science and Business Media LLC[DOI]
- Salvatore L. Ruggiero, "American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update", Journal of Oral and Maxillofacial Surgery, 72(10), pp.1938~1956 (2014), Elsevier BV[DOI]
- Amber L. Watters, "Intravenous bisphosphonate–related osteonecrosis of the jaw: Long-term follow-up of 109 patients", Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 115(2), pp.192~200 (2013), Elsevier BV[DOI]
- Katia Rupel, "A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ)", Oral Oncology, 50(11), pp.1049~1057 (2014), Elsevier BV[DOI]
- R. Fliefel, "Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review", International Journal of Oral and Maxillofacial Surgery, 44(5), pp.568~585 (2015), Elsevier BV[DOI]
- Claudine Tsao, "Oral Health Risk Factors for Bisphosphonate-Associated Jaw Osteonecrosis", Journal of Oral and Maxillofacial Surgery, 71(8), pp.1360~1366 (2013), Elsevier BV[DOI]
- F. Saad, "Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases", Annals of Oncology, 23(5), pp.1341~1347 (2012), Elsevier BV[DOI]
- S. Bocanegra-Pérez, "Use of platelet-rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw", International Journal of Oral and Maxillofacial Surgery, 41(11), pp.1410~1415 (2012), Elsevier BV[DOI]
- P Ceponis, "Hyperbaric oxygen therapy and osteonecrosis", Oral Diseases, 23(2), pp.141~151 (2016), Wiley[DOI]
- Marcos Martins Curi, "Bisphosphonate-Related Osteonecrosis of the Jaws–An Initial Case Series Report of Treatment Combining Partial Bone Resection and Autologous Platelet-Rich Plasma", Journal of Oral and Maxillofacial Surgery, 69(9), pp.2465~2472 (2011), Elsevier BV[DOI]
- John J. Freiberger, "Hyperbaric Oxygen Treatment and Bisphosphonate-Induced Osteonecrosis of the Jaw: A Case Series", Journal of Oral and Maxillofacial Surgery, 65(7), pp.1321~1327 (2007), Elsevier BV[DOI]
- Miriam Martos-Fernández, "Pentoxifylline, tocopherol, and clodronate for the treatment of mandibular osteoradionecrosis: a systematic review", Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 125(5), pp.431~439 (2018), Elsevier BV[DOI]
- Sylvie Delanian, "Complete Restoration of Refractory Mandibular Osteoradionecrosis by Prolonged Treatment with a Pentoxifylline-Tocopherol-Clodronate Combination (PENTOCLO): A Phase II Trial", International Journal of Radiation Oncology*Biology*Physics, 80(3), pp.832~839 (2011), Elsevier BV[DOI]
- Neuner P, "Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells", Immunology, 83(2), pp.262~267 (1994)
- Marie Magnusson, "Effects of pentoxifylline and its metabolites on platelet aggregation in whole blood from healthy humans", European Journal of Pharmacology, 581(3), pp.290~295 (2008), Elsevier BV[DOI]
- Qing Jiang, "Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy", Free Radical Biology and Medicine, 72, pp.76~90 (2014), Elsevier BV[DOI]
- Natalie H Beth-Tasdogan, "Interventions for managing medication-related osteonecrosis of the jaw", Cochrane Database of Systematic Reviews, 2017(10) (2017), Wiley[DOI]
- Elena M. Varoni, "Conservative Management of Medication-Related Osteonecrosis of the Jaws (MRONJ): A Retrospective Cohort Study", Antibiotics, 10(2), pp.195~ (2021), MDPI AG[DOI]
- Alan Ward, "Pentoxifylline", Drugs, 34(1), pp.50~97 (1987), Springer Science and Business Media LLC[DOI]
- Sylvie Delanian, "The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway", Radiotherapy and Oncology, 73(2), pp.119~131 (2004), Elsevier BV[DOI]
- Sylvie Delanian, "Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: A phase II trial", Head & Neck, 27(2), pp.114~123 (2005), Wiley[DOI]
- J. D'Souza, "Changing trends and the role of medical management on the outcome of patients treated for osteoradionecrosis of the mandible: experience from a regional head and neck unit", British Journal of Oral and Maxillofacial Surgery, 52(4), pp.356~362 (2014), Elsevier BV[DOI]
- Vinod Patel, "Prophylactic use of pentoxifylline and tocopherol in patients who require dental extractions after radiotherapy for cancer of the head and neck", British Journal of Oral and Maxillofacial Surgery, 54(5), pp.547~550 (2016), Elsevier BV[DOI]
- Gabrielle Delfrate, "Effect of pentoxifylline and α-tocopherol on medication-related osteonecrosis of the jaw in rats: Before and after dental extraction", Archives of Oral Biology, 137, pp.105397~ (2022), Elsevier BV[DOI]
- Lindberg AE, "Vitamin E: Nutrition, Side Effects, and Supplements" (2011), Nova Science Publishers, Inc
- Matthew S. Epstein, "Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series", Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 110(5), pp.593~596 (2010), Elsevier BV[DOI]
- 서미현, "The effects of pentoxifylline and tocopherol in jaw osteomyelitis", 대한구강악안면외과학회지, 46(1), pp.19~27 (2020), 대한구강악안면외과학회[DOI]
- Adepitan A. Owosho, "Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series", Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 122(4), pp.455~459 (2016), Elsevier BV[DOI]
- Michèle Magremanne, "Pentoxifylline and Tocopherol in the Treatment of Yearly Zoledronic Acid–Related Osteonecrosis of the Jaw in a Corticosteroid-Induced Osteoporosis", Journal of Oral and Maxillofacial Surgery, 72(2), pp.334~337 (2014), Elsevier BV[DOI]